Pranoprofenのヒトにおける体内動態
スポンサーリンク
概要
- 論文の詳細を見る
The pharmacokinetics of pranoprofen, 2-(5H-[1] benzopyrano [2,3-b] pyridin-7-yl) propionic acid (I) in humans were examined. 1-O-Acylglucuronide of I (II) and its isomer (III) were isolated from the human urine after oral administration of I. The stability of II was tested in order to establish the suitable conditions for the storage and handling of biological samples. Maximum stability of II was found at pH 3-4. Unchanged drugs, II and III were detected in the human plasma after oral administration of I. Plasma concentrations of these compounds reached the maximum at 1-2 h after the administration and thereafter decreased biphasically. From the urinary sample, 1-O-acylglucoside of I (IV) was detected in addition to unchanged drugs, II and III. Within 24 h after dosing, 1.3,84.0,7.0 and 0.6% of the dose were excreted as I, II, III and IV, respectively and the total urinary excretion amounted to 92.9% in term of unchanged drug.
- 社団法人日本薬学会の論文
- 1990-07-25
著者
関連論文
- Pranoprofenのヒトにおける体内動態
- 3H-Indoleの研究(第1報)Oxindole, Indolineを経る3,3-ジ置換3H-Indoleの新合成法
- 新規Thromboxane合成酵素阻害剤Sodium 4-[α-Hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoate(Y-20811)の体内動態(第2報)イヌにおける未変化体及び主代謝物のPharmacokinetics
- 新規Thromboxane合成酵素阻害剤Sodium 4-[α-Hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoate(Y-20811)の体内動態(第1報)イヌにおける尿中代謝物の単離と構造決定
- Pharmacokinetics and neuroendocrinological studies of bromperidol in schizophrenic patients.